发明名称 |
STABLE LIQUID FORMULATION OF BOTULINUM TOXIN |
摘要 |
<P>PROBLEM TO BE SOLVED: To provide a ready-to-use liquid formulation for use of a botulinum toxin that is easily transported, stored and used. <P>SOLUTION: A composition is for treating a patient who needs to check a cholinergic input to selected muscles, muscle clusters, glands or organs. The composition contains the ready-to-use, stable, pharmaceutical liquid formulation of the botulinum toxin for use of a pharmaceutically effective dosage. The formulation includes (a) pharmaceutically acceptable buffered physiological saline containing a buffer component selected from the group consisting of a phosphoric acid buffer, a phosphoric acid-citric acid buffer and a succinic acid buffer; (b) serum albumin; (c) the isolated botulinum toxin. The composition is stable as a liquid for at least an year at a temperature of ±10% of a temperature between 0-10°C or for at least 6 months at a temperature of ±10% of a temperature between 10-30°C. The composition is suitable for administration as a pharmaceutical agent to mammals without reconstruction. <P>COPYRIGHT: (C)2010,JPO&INPIT |
申请公布号 |
JP2010138186(A) |
申请公布日期 |
2010.06.24 |
申请号 |
JP20100043514 |
申请日期 |
2010.02.26 |
申请人 |
SOLSTICE NEUROSCIENCES INC |
发明人 |
MOYER ELIZABETH;HIRTZER PAMELA |
分类号 |
A61K9/08;A61K38/00;A61K8/64;A61K9/00;A61K35/74;A61K38/16;A61K38/48;A61K47/02;A61K47/04;A61K47/12;A61K47/42;A61P1/04;A61P1/06;A61P11/02;A61P11/06;A61P13/06;A61P15/06;A61P19/02;A61P21/00;A61P21/02;A61P25/00;A61P25/04;A61P25/06;A61P25/08;A61P25/14;A61P25/16;A61P25/18;A61P25/28;A61P27/02;A61P27/16;A61P43/00;A61Q19/00;A61Q19/08;C07K14/195 |
主分类号 |
A61K9/08 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|